BioAtla Investor Presentation Deck

Phase 1 & 2 Results in Stage IV Multi-Refractory Melanoma Complete Response Observed in 2 out of 2 ROR2+ Patients %change in Target Lesions 100 80 60 40 20 0 -20 -40 -60 -80 -100 0 bicatla 20 Data on file. ROR2 + Phase 2 Patient 40 60 80 Time (weeks) 100 120 140 ROR2 + Phase 1 Patient 160 Phase 1 Patient Details: ✓ Prior treatment failure: nivolumab followed by nivolumab + ipilimumab combination ✓Clearance of pulmonary metastases followed by normalization of adenopathy ✓ Continued CR off-treatment for over 2 yrs Oo Phase 2 Patient Details: ✓ Prior treatment failure: nivolumab followed by Dacarbazine ✓ Complete Response on 1st scan (3 doses) BioAtla| Overview 25

View entire presentation